Table 1.

Demographic, clinical, and laboratory characteristics of women on isoniazid and efavirenz during pregnancy and at postpartum

Characteristics (median and range, or n and %)	Participants in isoniazid PK analysis		Participants in efavirenz PK analysis
	Pregnancy (n = 420)	Postpartum (n = 637)	Pregnancy (n = 712)	Postpartum (n = 670)
Age, years	29 (18–45)	29 (19–42)	29 (18–45)	29 (18–45)
Weight, kg	68 (39–167)	62 (38–165)	67 (42–164)	61 (37–114)
Body mass index, kg/m2	27 (18–61)	24 (16–45)	27 (18–61)	25 (16–49)
Gestation/postnatal age, weeks, at PK sampling time	26 (14–34)	16 (7–23)	26 (14–34)	16 (7–23)
Baseline viral load, copies/mL	< 40 (< 40–237,000)	< 40 (< 40–465,000)	< 40 (< 40–237,000)	< 40 (< 40–465,000)
Drug regimen
On isoniazid	420 (100%)	637 (100%)	352 (49%)	540 (80%)
On efavirenz	371 (88%)	563 (88%)	712 (100%)	670 (100%)
On nevirapine	11 (3%)	47 (8%)	‐	‐
On lopinavir/ritonavir	5 (1%)	5 (1%)	‐	‐
On atazanavir/ritonavir	2 (0%)	2 (0%)	‐	‐
Days on EFV at PK sampling time	125 (18–3,800)	264 (1–4,228)	125 (18–3,800)	408 (1–4,228)

Drug metabolizing genotype	NAT 2 acetylation status		CYP2B6 metabolizer status
Rapid	52 (12%)	70 (11%)	168 (24%)	146 (22%)
Intermediate	140 (33%)	202 (32%)	299 (42%)	264 (40%)
Slow	159 (39%)	199 (31%)	118 (16%)	102 (15%)
Ultra‐slow	‐	‐	1 (0%)	2 (0%)
Missing	69 (16%)	166 (26%)	126 (18%)	156 (23%)

			CYP2A6 metabolizer status
Normal			501 (70%)	439 (65%)
Intermediate			81 (11%)	71 (11%)
Slow			4 (1%)	4 (1%)
Missing			126 (18%)	156 (23%)

Two hundred ten women had isoniazid profiles during both pregnancy and postpartum.

Five hundred ninety‐six women had efavirenz profiles available during both pregnancy and postpartum.

EFV, efavirenz; PK, pharmacokinetic.